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Hypothesizing that members of families enriched for longevity delay morbidity compared
to population controls and approximate the health-span of centenarians, we compared the
health-spans of older generation subjects of the Long Life Family Study (LLFS) to controls
without family history of longevity and to centenarians of the New England Centenarian
Study (NECS) using Bayesian parametric survival analysis. We estimated hazard ratios, the
ages at which specific percentiles of subjects had onsets of diseases, and the gain of years
of disease-free survival in the different cohorts compared to referent controls. Compared
to controls, LLFS subjects had lower hazards for cancer, cardiovascular disease, severe
dementia, diabetes, hypertension, osteoporosis, and stroke. The age at which 20% of
the LLFS siblings and probands had one or more age-related diseases was approximately
10 years later than NECS controls.While female NECS controls generally delayed the onset
of age-related diseases compared with males controls, these gender differences became
much less in the older generation of the LLFS and disappeared amongst the centenari-
ans of the NECS. The analyses demonstrate extended health-span in the older subjects of
the LLFS and suggest that this aging cohort provides an important resource to discover
genetic and environmental factors that promote prolonged health-span in addition to longer
life-span.
Keywords: health-span, longevity, onset of disease, survival analysis,Weibull regression
INTRODUCTION
The Long Life Family Study (LLFS) is an ongoing study of
longevity and healthy aging in 583 families and almost 5000
family members demonstrating clustering for longevity. Median
age of the probands and their siblings (the older generation or
“generation one”) at enrollment was 92 years with an age range
of 72–109 years. This substantial longevity was associated with
decreased prevalence of age-related diseases such as diabetes and
peripheral artery disease compared to subjects in the Framingham
Heart Study and Cardiovascular Health Study (1).
However, disease prevalence may fail to capture important dif-
ferences in health-span, that is, age of onset (2), particularly when
comparing individuals with average life-span to individuals with
extended life-span who may not escape morbidity but rather com-
press it toward the ends of their lives (3). Based on the hypothesis
that age of onset of disease is a more informative metric of health-
span than lifetime prevalence of disease, we set out to use survival
analyses to study the health-span of LLFS generation one rela-
tive to population and spousal controls without familial longevity.
In addition, we compare the health-span of LLFS generation one
to the health-span of centenarians enrolled in the New England
Centenarian Study (NECS) for whom we have demonstrated a
substantial delay of age of onset of major age-related diseases,
particularly for ages 105+ years (4).
MATERIALS AND METHODS
STUDY SUBJECTS
The LLFS enrolled subjects between 2006 and 2009 via three Amer-
ican and one Danish field centers. Probands were screened using
the Family Longevity Selection Score (FLoSS), which scored the
degree of familial longevity using sex and birth-year cohort sur-
vival probabilities of the proband and their siblings (5). Eligibility
of sibships for the study was based on a FLoSS score >7, and
lack of cognitive impairment in the proband and at least one
living sibling. The NECS has enrolled age-validated centenari-
ans, their offspring and controls throughout the USA since 1994
(6). The NECS provided two comparison groups for this study:
a control group of subjects enrolled because of either lack of
longevity in their deceased parents (one parent died at the average
life expectancy of their cohort and the other parent did not live
beyond the age of 85 years) or because they were spouses of cen-
tenarian offspring, and centenarians and nonagenarian siblings
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Table 1 | Characteristics of the subjects in the four groups.
LLFS probands and siblings LLFS spouses NECS nonagenarians and centenarians NECS controls
Number of subjects 1493 192 1807 433
Number of families 583 192 1397 333
Age at enrollmenta 92 (72–109) 85 (55–101) 100 (81–118) 72 (46–90)
Age last contacta 94 (72–110) 87 (58–102) 103 (87–119) 77 (47–96)
Birth-year cohortb 1916 (1898–1937) 1923 (1908–1953) 1900 (1880–1917) 1931 (1913–1957)
Follow upa 2 (0–6) 2 (0–4) 2 (0–13) 8 (0–10)
Male sex (% male) 709 (48) 42 (23) 456 (25) 234 (54)
Age last contacta – males 93 (75–108) 89 (66–102) 102 (88–115) 77 (47–90)
Age last contacta – females 95 (72–110) 87 (58–99) 103 (87–119) 77 (54–96)
Cancer (%) 26 22 19 32
COPD (%) 5 5 5 9
CVD (%) 44 37 48 27
Dementia (%) 9 5 31 4
Diabetes (%) 9 11 7 17
Hypertension (%) 54 62 43 61
Osteoporosis (%) 41 39 28 27
Parkinson’s (%) 1 1 2 2
Stroke (%) 19 15 19 11
The table reports summary demographic and health profiles in terms of prevalence of age-related diseases at last contact.
aMedian age (range) in years.
bMedian year (range).
of centenarians (Table 1). All participants underwent informed
consent.
DATA
In both LLFS and NECS, socio-demographic, vital status, and
medical history data were collected via mailed questionnaires
or in-person visits. Medical history questionnaires in both stud-
ies asked similar questions. Next-of-kin assisted when neces-
sary. Ages of onset for the following diseases were used for the
analysis: cancer (excluding non-melanoma skin cancers), chronic
obstructive pulmonary disease (COPD: emphysema, bronchiec-
tasis, and/or chronic bronchitis), cardiovascular disease (CVD:
myocardial infarction, angina pectoris, congestive heart failure,
atrial fibrillation, and/or valvular heart disease), dementia, dia-
betes, hypertension, osteoporosis (as diagnosed, or reported hip,
wrist, and/or vertebral fracture at age 50 and older), Parkinson’s
disease, or stroke. Because dementia was based on self- or proxy-
reported medical history with possibly low sensitivity, a report
of dementia should be considered as “severe dementia” rather
than mild or moderate cognitive impairment. The selected dis-
eases comprise the top 10 most prevalent diseases to afflict people
age 65+ years according to the United States Centers for Disease
Control (CDC) (7). In the NECS we compared subject’s (or their
proxy’s) responses to the medical history questionnaire with their
medical records for a random subsample of 90 subjects and for the
diseases included in the analysis reported here the agreement was
100% (4). Overall morbidity was defined as one or more of the
following: cancer, COPD, CVD, dementia, diabetes, or stroke. As
in (4), hypertension was not included in the definition of overall
morbidity because, if present, it was being treated with medica-
tion, thus markedly decreasing its effect upon morbidity. In both
the NECS and LLFS, annual follow ups are conducted over the
phone to update information on vital status and changes in health
status and medications. The medical history data at enrollment
and data from annual follow-ups were merged to calculate age of
onset of disease based on the age at first occurrence. In both LLFS
and NECS, follow up data were updated to November, 2012.
STATISTICAL METHODS
Patients’ characteristics are displayed by median, range, and pro-
portions (Table 1). Disease-free survival stratified by gender and
sample cohort is described by Kaplan–Meier curves (Figures 1–8).
Last age of contact or age at death was used for censoring. Signif-
icant differences in hazard rates among groups and gender were
tested using Bayesian parametric survival analysis with Weibull
regression (4). Within sibship correlation was modeled using a
normally distributed random effect per family in the log-hazard
function (8). Comparisons between LLFS probands and siblings
and their spouses relative to NECS centenarians and controls were
summarized by hazard ratios (HRs) (Table 2), by the age estimated
to reach specific percentiles of survival (Figure 9), and by the gains
of each disease-free survival in years, compared to NECS controls
(Table 3). The percentiles of survival for each disease are shown in
Table 3 and were chosen to approximate the reported prevalence
for each disease amongst older adults. Specifically, 20% prevalence
for cancer for ages 65–80 was based on CDC Wonder1 (year 2009);
25% prevalence CVD for ages 65 and older was based on MMWR2;
25% prevalence for dementia was based on average of prevalence
1http://wonder.cdc.gov/cancer.html
2http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6040a1.htm
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FIGURE 1 | Kaplan–Meier curves of survival free of cancer in NECS controls (NECS.C, black line), LLFS controls (LLFS.C, green line), LLFS probands
and siblings (LLFS.P, blue line), and NECS centenarians (NECS.P, red line). Left panel: females; right panel: males. Skin cancer was not included.
FIGURE 2 | Kaplan–Meier curves of survival free of cardiovascular
disease (CVD) in NECS controls (NECS.C, black line), LLFS controls
(LLFS.C, green line), LLFS probands and siblings (LLFS.P, blue line), and
NECS centenarians (NECS.P, red line). CVD definition included myocardial
infarction, angina pectoris, congestive heart failure, atrial fibrillation, and/or
valvular heart disease. Left panel: females; right panel: males.
FIGURE 3 | Kaplan–Meier curves of survival free of severe dementia in NECS controls (NECS.C, black line), LLFS controls (LLFS.C, green line), LLFS
probands and siblings (LLFS.P, blue line), and NECS centenarians (NECS.P, red line). Left panel: females; right panel: males.
for age groups 65 and older and 85 and older reported by the
Alzheimer’s organization in 20113; 10% prevalence diabetes was
based on CDC reported national statistics in 20114; 25% preva-
lence hypertension was based on reference (9); 50% prevalence of
3http://www.alz.org/downloads/facts_figures_2011.pdf
4http://www.cdc.gov/diabetes/pubs/factsheet11/tables1_2.htm
osteoporosis was based on NHANES data5; and 25% stroke was
based on data reported in (10).
Models with two-way interactions between gender and group
were fitted and Bayesian estimates of the HRs,ages at which specific
proportions of the different comparison groups were disease-free
5http://www.cdc.gov/nchs/data/nhanes/databriefs/osteoporosis.pdf
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FIGURE 4 | Kaplan–Meier curves of survival free of diabetes in NECS controls (NECS.C, black line), LLFS controls (LLFS.C, green line), LLFS probands
and siblings (LLFS.P, blue line), and NECS centenarians (NECS.P, red line). Left panel: females; right panel: males.
FIGURE 5 | Kaplan–Meier curves of survival free of hypertension in NECS controls (NECS.C, black line), LLFS controls (LLFS.C, green line), LLFS
probands and siblings (LLFS.P, blue line), and NECS centenarians (NECS.P, red line). Left panel: females; Right panel: males.
FIGURE 6 | Kaplan–Meier curves of survival free of osteoporosis in NECS
controls (NECS.C, black line), LLFS controls (LLFS.C, green line), LLFS
probands and siblings (LLFS.P, blue line), and NECS centenarians
(NECS.P, red line). Osteoporosis age of onset was based on the earliest
diagnosis or reported hip, wrist, and/or vertebral fracture at age 50 and older.
Left panel: females; right panel: males.
and gain of disease-free survival were computed using Markov
Chain Monte Carlo (11), as in (4). Uninformative priors were
assumed for all parameters, and at least 10,000 simulated val-
ues were used to estimate the parameters as the medians of
the samples generated from the posterior distributions. Credible
intervals were estimated using the 2.5 and 97.5 percentiles from
the samples generated from the posterior distribution. Statistical
significance of HRs was based on 95% credible intervals not con-
taining 1, while statistical significance of gains of disease-free
survival was based on 95% credible intervals not containing 0.
The survival distributions estimated using Weibull regression were
plotted together with the Kaplan–Meier curves to evaluate ade-
quacy of model fitting by visual inspection (see Supplementary
Material).
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FIGURE 7 | Kaplan–Meier curves of survival free of stroke in NECS controls (NECS.C, black line), LLFS controls (LLFS.C, green line), LLFS probands
and siblings (LLFS.P, blue line), and NECS centenarians (NECS.P, red line). Left panel: females; right panel: males.
FIGURE 8 | Kaplan–Meier curves of survival free of morbidity in NECS
controls (NECS.C, black line), LLFS controls (LLFS.C, green line), LLFS
probands and siblings (LLFS.P, blue line), and NECS centenarians
(NECS.P, red line). Morbidity was defined as one or more of the following:
cancer, COPD, CVD, dementia, diabetes, or stroke. Left panel: females; right
panel: males.
All analyses were conducted in OpenBugs6 and R 2.14.
RESULTS
Table 1 shows summary statistics of the 4 comparison groups
included in the analysis and the prevalences of age-related diseases.
The NECS centenarians included 120 supercentenarians (age at
death≥ 110 years) for most of whom we observed compression of
morbidity (4).
Figures 1–8 show gender and disease-specific Kaplan–Meier
curves for survival free of each of seven age-related diseases and
overall morbidity free survival in the four groups. COPD and
Parkinson’s disease were rare in long-lived individuals and were
not included in these analyses (COPD prevalence was <5% and
Parkinson’s disease prevalence was <2%). For each of the seven
diseases and overall morbidity, the Kaplan–Meier curves show a
consistent pattern of delayed age of onset in the order: NECS con-
trols< LLFS controls< LLFS proband generation<NECS cente-
narians. An exception is severe dementia, where the age of onset
tended to be delayed in LLFS probands and siblings relative to the
other groups. An additional finding in Figures 1–8 is the effect of
gender: amongst NECS controls, females consistently delayed the
6http://mathstat.helsinki.fi/openbugs/Home.html
onset of disease compared to males. However, the delay of disease
onset in females relative to males was more moderate in partic-
ipants of the LLFS and practically disappeared amongst NECS
centenarians. Exceptions were hypertension, delayed only in male
NECS centenarians, and osteoporosis, delayed in males of all four
groups.
Table 2 shows the HRs estimated by Bayesian–Weibull regres-
sion. Gender was a significant effect modifier of survival free of
cancer, CVD, hypertension, osteoporosis, stroke, and overall mor-
bidity but not severe dementia or diabetes. The effect of gender
varied widely and these differences translated into varying years of
disease-free survival (Table 3; Figure 9). We next summarize the
results by disease.
CANCER
Female NECS controls had decreased risk of cancer compared to
male NECS controls (HR: 0.65, 95% CI: 0.43; 0.93). Similarly,
female LLFS probands and siblings had decreased risk of cancer
compared to male probands and siblings (HR: 0.74, 95% CI: 0.62;
0.87) but gender did not modify the risk for cancer in the other
groups. The HR for cancer in female probands and siblings of the
LLFS was 0.28 compared to female NECS controls (95% CI: 0.20;
0.39) and even smaller for male probands and siblings compared
to male NECS controls (HR: 0.24, 95% CI: 0.19; 0.31). The HR
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for cancer of male NECS centenarians was 0.13 compared to male
NECS controls (95% CI: 0.10; 0.17) and 0.18 for female NECS cen-
tenarians compared to female NECS controls (95% CI: 0.14; 0.25).
Figure 9 shows that, by the age of approximately 70 years in males
and 75 years in females, 20% of NECS controls had a cancer event.
The age at which the same percentage of LLFS spousal controls
had a cancer event was approximately 85 years, and the age was
delayed to approximately 90 years in female LLFS probands and
siblings and past 95 years in NECS centenarians. Table 3 shows
the gain of years of cancer-free survival. In LLFS probands and
siblings, the estimated age at which 20% of subjects had a cancer
event was delayed by approximately 17 years compared to NECS
controls for both males and females.
CARDIOVASCULAR DISEASE
In both the NECS and LLFS, female controls had lower risk of
CVD compared to male controls (Table 2: NECS HR: 0.52, 95%
CI: 0.35; 0.77; LLFS HR: 0.44, 95% CI: 0.28; 0.74). The gender
difference decreased amongst LLFS probands and siblings and
NECS centenarians (HR: 0.70, 95% CI: 0.62; 0.78) and became
not significant in NECS centenarians. LLFS male probands and
siblings had smaller risk of CVD only compared to male NECS
controls (HR: 0.69, 95% CI: 0.54; 0.8) while the decrease in risk
of female probands and siblings compared to NECS female con-
trols did not reach statistical significance. NECS centenarians had
smaller risk for CVD compared to NECS controls and the risk
was substantially smaller for males (HR: 0.44, 95% CI: 0.33; 0.57)
than females (HR: 0.76, 95% CI: 0.56; 1.00). The difference in HR
for NECS centenarians and LLFS probands and siblings was not
significant (note the overlapping interval estimates). The reduced
hazard rates translated into a 2–6 year delay in the age at which
25% of LLFS probands and siblings had a CVD event (Table 3;
Figure 9), compared to NECS controls. The gain in years of CVD
free survival was larger in NECS centenarians than LLFS probands
and siblings, but the difference was not statistically significant.
SEVERE DEMENTIA
Gender did not significantly change the risk for severe dementia in
NECS controls and LLFS subjects,while female NECS centenarians
had higher risk for dementia than male NECS centenarians (HR:
1.39, 95% CI: 1.07; 1.87). LLFS subjects had lower risk of dementia
compared to NECS controls (male HR: 0.23, 95% CI: 0.13; 0.46,
female HR: 0.39, 95% CI: 0.19; 0.97). The risk was slightly lower
than the risk of severe dementia in NECS centenarians relative to
NECS controls. The lower risk for dementia of LLFS subjects rela-
tive to NECS controls translated into a gain of 8.8–13.4 years in age
at which 25% of the LLFS subjects had severe dementia compared
to NECS controls (Table 3; Figure 9).
DIABETES
With the exception of LLFS spouses, gender did not significantly
modify the risk for diabetes in any of the four groups. LLFS
probands and siblings had a substantially smaller risks of dia-
betes relative to NECS controls (HR: 0.13 for males and HR:
0.11 for females). Compared to NECS controls, LLFS spouses had
smaller risk of diabetes, and so did NECS centenarians (HR: 0.08)
(Table 2). The estimated age at which 10% of the sample had his-
tory of diabetes was 73 years for NECS controls, between 80 and
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FIGURE 9 | Estimates and 95% credible intervals of the age at which p% of subjects in the various groups had onset of disease. The inset describes the
groups’ labels. Rationale for the choice of percentages p is in methods.
90 years for LLFS spouses, 95 years for LLFS siblings and probands
and 99 years for NECS centenarians (Figure 9). Table 3 shows that
LLFS probands and siblings delayed the age at which 10% of the
cohort had diabetes by about 20 years relative to NECS controls.
The delay in NECS centenarians was 25 years.
HYPERTENSION
The risk for hypertension was significantly smaller in LLFS
probands and siblings than NECS controls (male HR: 0.27, 95%
CI: 0.14; 0.51, female HR: 0.33, 95% CI: 0.28; 0.40). NECS cen-
tenarians had similar change in risk compared to NECS controls:
HR: 0.15 (95% CI: 0.08; 0.28) in male centenarians relative to
male NECS controls and HR: 0.17 (95% CI: 0.15; 0.20) in female
centenarians relative to female NECS controls. Female NECS cen-
tenarians also had greater risk for hypertension relative to male
centenarians although the increase was only marginally signifi-
cant (HR: 1.16, 95% CI: 0.99; 1.34). The risk for hypertension in
LLFS female spouses was 0.56 times the risk in NECS controls
(95% CI: 0.44; 0.71) and smaller in males (HR: 0.3, 95% CI: 0.15;
0.72). LLFS probands and siblings delayed the age at which 25%
subjects had hypertension by about 18 years compared to controls
from the NECS (Figure 9; Table 3). The reduced risk for hyper-
tension in female NECS centenarians compared to male NECS
centenarians translated into a 1.8 years delay of the age at which
25% subjects had hypertension but the gain was not significant
(95% CI:−0.2; 5.8).
OSTEOPOROSIS
This disease was more prevalent and occurred at earlier ages in
females than males of all four groups (Figure 6). The regression
analysis showed that females had significant higher risk than males
in the four groups but the risk decreased within LLFS subjects
(HR: 2.54 for LLFS spouses and HR: 2.38 for LLFS probands and
siblings) and NECS centenarians (HR: 1.80) compared to NECS
controls (HR: 4.4). However, the overlapping credible intervals
show that the trend was not significant. LLFS and NECS subjects
delayed the age at which 50% subjects had the disease by 8–9 years
compared to male NECS controls and between 16 and 22 years
compared to female NECS controls. Male NECS centenarians had
a 13.5 years gain in the age at which 50% subjects had the dis-
ease compared to female NECS centenarians and the gain was
significant (95% CI:−15.5;−11.5).
STROKE
The HR for stroke in LLFS male probands and siblings compared
to male NECS controls was 0.30 (95% CI: 0.21; 0.46) and 0.49
when compared to female NECS controls (95% CI: 0.29; 0.92).
The risk was smaller in NECS male centenarians (HR: 0.16, 95%
CI: 0.11; 0.25) relative to male NECS controls and relative to female
NECS controls (HR: 0.25, 95% CI: 0.15; 0.47). The age at which
25% of controls had a stroke event was approximately 87 years for
males and approximately 95 years for females, 98 years for LLFS
probands and siblings and >105 years in NECS centenarians.
OVERALL MORBIDITY
The onset of morbidity was delayed in female NECS controls com-
pared to male NECS controls, and in LLFS and NECS subjects
compared to controls (Figure 8). However, gender differences in
LLFS spouses (HR: 0.81, 95% CI: 0.45; 1.32) and NECS centenari-
ans (HR: 0.93, 95% CI: 0.78; 1.07) were not significant. LLFS male
probands and siblings had 0.41 times the risk of morbidity com-
pared to male NECS controls (HR: 0.41, 95% CI: 0.34; 0.50) and
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Table 3 | Sex-specific gain in years of disease-free survival of LLFS subjects and NECS centenarians relative to NECS controls.
Disease Cont.F vs.
Cont.M
LLFS.C.M vs.
Cont.M
LLFS.C.F vs.
Cont.F
LLFS.P.M vs.
Cont.M
LLFS.P.F vs.
Cont.F
NECS.M vs.
Cont.M
NECS.F vs.
Cont.F
Cancer (p=0.20) 5.0
(0.9; 9.6)
15.7
(8.5; 24.4)
11.1
(5.6; 16.9)
17.5
(14.4; 20.5)
16.7
(12.6; 20.4)
26.7
(23.3; 30.0)
23.02
(19.0; 26.6)
CVD (p=0.25) 10.0
(3.9; 15.9)
−2.7
(−9.1; 4.4)
−0.14
(−6.5; 6.3)
6.0
(1.8; 9.8)
2.0
(−3.0; 6.8)
13.3
(9.0; 17.7)
5.2
(0.3; 10.0)
Dementia (p=0.25) 3.4
(−5.4; 12.9)
16.4
(4.3; 27.2)
6.9
(−2.3; 15.5)
13.4
(7.3; 18.8)
8.8
(0.3; 15.3)
11.9
(5.6; 17.1)
5.2
(−3.3; 11.5)
Diabetes (p=0.10) 0.78
(−3.3; 5.0)
6.4
(0.9; 12.9)
17.2
(10.7; 23.3)
19.1
(15.6; 22.4)
20.9
(17.0; 24.5)
24.7
(21.2; 28.0)
25.3
(21.6; 28.6)
HTN (p=0.25) −0.0
(−8.5; 7.4)
8.0
(4.6; 11.8)
8.0
(4.6; 11.5)
19.6
(10.8; 27.4)
16.0
(13.6; 18.2)
30.8
(21.7; 38.8)
28
(25.7; 30.2)
Osteoporosis (p=0.50) −22.8
(−28.9; −16.6)
5.2
(−5.4; 16.6)
12.3
(7.2; 17.3)
7.7
(2.1; 13.4)
15.6
(11.9; 19.0)
9.6
(3.6; 15.5)
21.8
(18.1; 25.2)
Stroke (p=0.25) 5.5
(−0.6; 13.1)
5.7
(−1.4; 14.2)
6.1
(−2.2; 13.7)
12.9
(8.5; 16.7)
8.1
(1.0; 13.5)
20.7
(15.9; 24.7)
16.1
(9.1; 21.2)
Morbidity (p=0.20) 5.6
(2.6; 8.8)
10.8
(4.3; 17.7)
8.1
(4.1; 12.3)
11.3
(9.0; 13.5)
10.0
(7.0; 12.8)
18.9
(16.1; 21.7)
14.6
(11.6; 17.3)
Years delay and 95% credible intervals (in parenthesis) to have a proportion p of the group affected with disease.The delays were estimated using Weibull regression
and the formula age= (ln(1/p)/λ)1/γ where λ and v are the parameters of the hazard function h(age)=λv(ageγ−1) (see Supplementary Material for details).The proportion
p used for each disease is reported in column 1. Columns report gain in years of disease-free survival in female controls from the NECS relative to male controls
(Cont.F vs. Cont.M); in male spousal controls from the LLFS relative to NECS male controls (LLFS.C.M vs. Cont.M); in female spousal controls from the LLFS
relative to NECS female controls (LLFS.C.F vs. Cont.F); in male probands and siblings from the LLFS relative to NECS male controls (LLFS.P.M vs. Cont.M); in female
probands and siblings from the LLFS relative to NECS female controls (LLFS.P.F vs. Cont.F); in male NECS centenarians relative to NECS male controls (NECS.M
vs. Cont.M); in female NECS centenarians relative to NECS female controls (NECS.F vs. Cont.F).
0.48 times the risk compared to female NECS controls (HR: 0.48,
95% CI: 0.39; 0.60). The risk for morbidity was even smaller in
NECS centenarians. The age at which 20% LLFS probands and sib-
lings experienced morbidity was delayed by 11.3 years relative to
male NECS controls and 10 years relative to female NECS controls
(Table 3).
DISCUSSION
The analysis showed that LLFS probands and siblings markedly
delay the age of onset of major age-related diseases relative
to NECS controls. The LLFS subjects’ overall disease-free sur-
vival was almost comparable to that of NECS centenarians
with the exception of severe dementia where the LLFS sub-
jects demonstrated an even greater delay. This finding could be
due to the LLFS inclusion criterion that required the proband
and at least one sibling to be able to provide their own con-
sents at the time of enrollment. Pulmonary disease was much
less prevalent in LLFS probands and siblings and NECS cente-
narians (5%) compared to NECS controls and this result sup-
ports the importance of pulmonary health for longevity and
the fact that poor pulmonary function is a strong predictor of
mortality (12, 13).
A similar pattern of delay in age of onset was observed for nearly
all the age-related diseases included in these analyses. Perhaps
members of these families age at slower rates and they have biolog-
ical factors that impact upon both rate of aging and pathogeneses
of age-related diseases. In general, women delay age-related dis-
eases such as CVD and stroke by about 5–10 years compared to
men (14). However, several centenarian studies have shown that
this female advantage disappears at very old ages (15, 16). In this
study of LLFS subjects, we similarly found that overall morbid-
ity and disease-free survival became indistinguishable between
males and females at the oldest ages. Exceptions were osteoporosis
which was delayed in males compared to females in all groups,
and hypertension. A generally accepted hypothesis for this con-
vergence in disease rates is that men who develop age-related
diseases at younger ages die, leaving behind a selected cohort
of male survivors with age-related disease rates similar to aged
females. However, these men are relatively rare at the oldest ages
and amongst extremely old subjects aged 110+ years, the female
to male ratio is 9 to 1 (4).
A surprising result of the analysis was the delay in onset of mor-
bidity of the LLFS spouses. This delay could be due to the fact that
at enrollment, the spouses have already achieved ages substantially
beyond average life expectancy for their cohort. The spouses might
also share environmental factors and life styles of LLFS probands
and siblings that are conducive to increased health-span. Addi-
tional analyses that correlate environmental and genetic factors to
the health-spans of these subjects will be necessary to understand
this result (17).
This study aimed at comparing the health-spans of LLFS sub-
jects relative to NECS controls and centenarians without trying
to discover risk factors associated with the different patterns of
survival. Future analyses that integrate genetic and non-genetic
data will be necessary to discover factors that promote and extend
health-span. The study described here establishes the LLFS as an
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invaluable resource to discover genetic and environmental factors
that promote exceptional health-span and life-span.
LIMITATIONS
A limitation of this study is that we relied upon self-report for
ascertainment of the ages of onset of the various diseases. How-
ever for all of the diseases included in the analysis, there was a very
strong correlation between these reports and the subjects’ medical
records for a subsample of NECS subjects. Also, all participants
were subjected to similar methods of data collection and there-
fore, comparisons between them should still yield valid results, at
least relative to one another. The problem of likely decreased sensi-
tivity associated with self-report for diseases such as dementia and
stroke can be minimized in future analysis of LLFS data by relying
upon direct functional and diagnostic measures that have been
performed on all subjects. Unfortunately, these do not help us in
determining age of onset for diseases that have already become
clinically evident.
An additional limitation is that this analysis combines reported
medical history with prospectively collected data about onset of
diseases in highly selected subjects, so that the HRs comparing
subjects selected for familial longevity to controls selected for
lack of familial longevity may be influenced by a survivor effect.
Although this limitation does not affect the comparative descrip-
tion of the health-span of the study subjects and provides evidence
that the LLFS is a valuable resource for studies of healthy aging and
longevity, the magnitude of the HRs may not be directly applicable
to the general population. The study subjects are currently fol-
lowed up and future analyses of the offspring cohort will provide
more general results.
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